ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Circulating Tumor DNA Diagnostics Market Research Report 2025
Published Date: March 2025
|
Report Code: QYRE-Auto-0E12052
Home | Market Reports | Science| Biological Sciences
Global Circulating Tumor DNA Diagnostics Market Research Report 2022
BUY CHAPTERS

Global Circulating Tumor DNA Diagnostics Market Research Report 2025

Code: QYRE-Auto-0E12052
Report
March 2025
Pages:74
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
GRAIL
Biodesix
Exosome Diagnostics
Freenome
Inivata Ltd
Personal Genome Diagnostics, Inc.
CellMax Life
GUARDANT HEALTH, INC
LungLife AI, Inc.

Circulating Tumor DNA Diagnostics Market Size

The global market for Circulating Tumor DNA Diagnostics was valued at US$ 14010 million in the year 2024 and is projected to reach a revised size of US$ 20410 million by 2031, growing at a CAGR of 5.6% during the forecast period.

Circulating Tumor DNA Diagnostics Market

Circulating Tumor DNA Diagnostics Market

Circulating tumor DNA (ctDNA) diagnostics, also known as liquid biopsy, is a non-invasive method for detecting and analyzing genetic alterations associated with cancer. This approach involves the identification of DNA fragments released by cancer cells into the bloodstream. These fragments, known as circulating tumor DNA, carry genetic information that can provide insights into the presence, characteristics, and progression of cancer.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Circulating Tumor DNA Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Circulating Tumor DNA Diagnostics.
The Circulating Tumor DNA Diagnostics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Circulating Tumor DNA Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Circulating Tumor DNA Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Circulating Tumor DNA Diagnostics Market Report

Report Metric Details
Report Name Circulating Tumor DNA Diagnostics Market
Accounted market size in year US$ 14010 million
Forecasted market size in 2031 US$ 20410 million
CAGR 5.6%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Grail, Inc., Guardant Health, Inc., Biodesix, Inc., Exosome Diagnostics, Freenome Inc., LungLife AI, Inc., Inivata Ltd., Personal Genome Diagnostics, Inc., CellMax Life
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Circulating Tumor DNA Diagnostics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Circulating Tumor DNA Diagnostics Market growing?

Ans: The Circulating Tumor DNA Diagnostics Market witnessing a CAGR of 5.6% during the forecast period 2025-2031.

What is the Circulating Tumor DNA Diagnostics Market size in 2031?

Ans: The Circulating Tumor DNA Diagnostics Market size in 2031 will be US$ 20410 million.

Who are the main players in the Circulating Tumor DNA Diagnostics Market report?

Ans: The main players in the Circulating Tumor DNA Diagnostics Market are Grail, Inc., Guardant Health, Inc., Biodesix, Inc., Exosome Diagnostics, Freenome Inc., LungLife AI, Inc., Inivata Ltd., Personal Genome Diagnostics, Inc., CellMax Life

What are the Application segmentation covered in the Circulating Tumor DNA Diagnostics Market report?

Ans: The Applications covered in the Circulating Tumor DNA Diagnostics Market report are Hospitals, Diagnostics Laboratories, Research Laboratories, Academic Research Institutes

What are the Type segmentation covered in the Circulating Tumor DNA Diagnostics Market report?

Ans: The Types covered in the Circulating Tumor DNA Diagnostics Market report are Test Kits, Reagents

Recommended Reports

Cancer Diagnostics

Tumor Cell Detection

Molecular & Liquid Biopsy

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Circulating Tumor DNA Diagnostics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Test Kits
1.2.3 Reagents
1.3 Market by Application
1.3.1 Global Circulating Tumor DNA Diagnostics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Diagnostics Laboratories
1.3.4 Research Laboratories
1.3.5 Academic Research Institutes
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Circulating Tumor DNA Diagnostics Market Perspective (2020-2031)
2.2 Global Circulating Tumor DNA Diagnostics Growth Trends by Region
2.2.1 Global Circulating Tumor DNA Diagnostics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Circulating Tumor DNA Diagnostics Historic Market Size by Region (2020-2025)
2.2.3 Circulating Tumor DNA Diagnostics Forecasted Market Size by Region (2026-2031)
2.3 Circulating Tumor DNA Diagnostics Market Dynamics
2.3.1 Circulating Tumor DNA Diagnostics Industry Trends
2.3.2 Circulating Tumor DNA Diagnostics Market Drivers
2.3.3 Circulating Tumor DNA Diagnostics Market Challenges
2.3.4 Circulating Tumor DNA Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Circulating Tumor DNA Diagnostics Players by Revenue
3.1.1 Global Top Circulating Tumor DNA Diagnostics Players by Revenue (2020-2025)
3.1.2 Global Circulating Tumor DNA Diagnostics Revenue Market Share by Players (2020-2025)
3.2 Global Circulating Tumor DNA Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Circulating Tumor DNA Diagnostics Revenue
3.4 Global Circulating Tumor DNA Diagnostics Market Concentration Ratio
3.4.1 Global Circulating Tumor DNA Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Circulating Tumor DNA Diagnostics Revenue in 2024
3.5 Global Key Players of Circulating Tumor DNA Diagnostics Head office and Area Served
3.6 Global Key Players of Circulating Tumor DNA Diagnostics, Product and Application
3.7 Global Key Players of Circulating Tumor DNA Diagnostics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Circulating Tumor DNA Diagnostics Breakdown Data by Type
4.1 Global Circulating Tumor DNA Diagnostics Historic Market Size by Type (2020-2025)
4.2 Global Circulating Tumor DNA Diagnostics Forecasted Market Size by Type (2026-2031)
5 Circulating Tumor DNA Diagnostics Breakdown Data by Application
5.1 Global Circulating Tumor DNA Diagnostics Historic Market Size by Application (2020-2025)
5.2 Global Circulating Tumor DNA Diagnostics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Circulating Tumor DNA Diagnostics Market Size (2020-2031)
6.2 North America Circulating Tumor DNA Diagnostics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Circulating Tumor DNA Diagnostics Market Size by Country (2020-2025)
6.4 North America Circulating Tumor DNA Diagnostics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Circulating Tumor DNA Diagnostics Market Size (2020-2031)
7.2 Europe Circulating Tumor DNA Diagnostics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Circulating Tumor DNA Diagnostics Market Size by Country (2020-2025)
7.4 Europe Circulating Tumor DNA Diagnostics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Circulating Tumor DNA Diagnostics Market Size (2020-2031)
8.2 Asia-Pacific Circulating Tumor DNA Diagnostics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Circulating Tumor DNA Diagnostics Market Size by Region (2020-2025)
8.4 Asia-Pacific Circulating Tumor DNA Diagnostics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Circulating Tumor DNA Diagnostics Market Size (2020-2031)
9.2 Latin America Circulating Tumor DNA Diagnostics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Circulating Tumor DNA Diagnostics Market Size by Country (2020-2025)
9.4 Latin America Circulating Tumor DNA Diagnostics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Circulating Tumor DNA Diagnostics Market Size (2020-2031)
10.2 Middle East & Africa Circulating Tumor DNA Diagnostics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Circulating Tumor DNA Diagnostics Market Size by Country (2020-2025)
10.4 Middle East & Africa Circulating Tumor DNA Diagnostics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Grail, Inc.
11.1.1 Grail, Inc. Company Details
11.1.2 Grail, Inc. Business Overview
11.1.3 Grail, Inc. Circulating Tumor DNA Diagnostics Introduction
11.1.4 Grail, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2020-2025)
11.1.5 Grail, Inc. Recent Development
11.2 Guardant Health, Inc.
11.2.1 Guardant Health, Inc. Company Details
11.2.2 Guardant Health, Inc. Business Overview
11.2.3 Guardant Health, Inc. Circulating Tumor DNA Diagnostics Introduction
11.2.4 Guardant Health, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2020-2025)
11.2.5 Guardant Health, Inc. Recent Development
11.3 Biodesix, Inc.
11.3.1 Biodesix, Inc. Company Details
11.3.2 Biodesix, Inc. Business Overview
11.3.3 Biodesix, Inc. Circulating Tumor DNA Diagnostics Introduction
11.3.4 Biodesix, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2020-2025)
11.3.5 Biodesix, Inc. Recent Development
11.4 Exosome Diagnostics
11.4.1 Exosome Diagnostics Company Details
11.4.2 Exosome Diagnostics Business Overview
11.4.3 Exosome Diagnostics Circulating Tumor DNA Diagnostics Introduction
11.4.4 Exosome Diagnostics Revenue in Circulating Tumor DNA Diagnostics Business (2020-2025)
11.4.5 Exosome Diagnostics Recent Development
11.5 Freenome Inc.
11.5.1 Freenome Inc. Company Details
11.5.2 Freenome Inc. Business Overview
11.5.3 Freenome Inc. Circulating Tumor DNA Diagnostics Introduction
11.5.4 Freenome Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2020-2025)
11.5.5 Freenome Inc. Recent Development
11.6 LungLife AI, Inc.
11.6.1 LungLife AI, Inc. Company Details
11.6.2 LungLife AI, Inc. Business Overview
11.6.3 LungLife AI, Inc. Circulating Tumor DNA Diagnostics Introduction
11.6.4 LungLife AI, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2020-2025)
11.6.5 LungLife AI, Inc. Recent Development
11.7 Inivata Ltd.
11.7.1 Inivata Ltd. Company Details
11.7.2 Inivata Ltd. Business Overview
11.7.3 Inivata Ltd. Circulating Tumor DNA Diagnostics Introduction
11.7.4 Inivata Ltd. Revenue in Circulating Tumor DNA Diagnostics Business (2020-2025)
11.7.5 Inivata Ltd. Recent Development
11.8 Personal Genome Diagnostics, Inc.
11.8.1 Personal Genome Diagnostics, Inc. Company Details
11.8.2 Personal Genome Diagnostics, Inc. Business Overview
11.8.3 Personal Genome Diagnostics, Inc. Circulating Tumor DNA Diagnostics Introduction
11.8.4 Personal Genome Diagnostics, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2020-2025)
11.8.5 Personal Genome Diagnostics, Inc. Recent Development
11.9 CellMax Life
11.9.1 CellMax Life Company Details
11.9.2 CellMax Life Business Overview
11.9.3 CellMax Life Circulating Tumor DNA Diagnostics Introduction
11.9.4 CellMax Life Revenue in Circulating Tumor DNA Diagnostics Business (2020-2025)
11.9.5 CellMax Life Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
GRAIL
Biodesix
Exosome Diagnostics
Freenome
Inivata Ltd
Personal Genome Diagnostics, Inc.
CellMax Life
GUARDANT HEALTH, INC
LungLife AI, Inc.
List of Tables
 Table 1. Global Circulating Tumor DNA Diagnostics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Test Kits
 Table 3. Key Players of Reagents
 Table 4. Global Circulating Tumor DNA Diagnostics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 5. Global Circulating Tumor DNA Diagnostics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Circulating Tumor DNA Diagnostics Market Size by Region (2020-2025) & (US$ Million)
 Table 7. Global Circulating Tumor DNA Diagnostics Market Share by Region (2020-2025)
 Table 8. Global Circulating Tumor DNA Diagnostics Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 9. Global Circulating Tumor DNA Diagnostics Market Share by Region (2026-2031)
 Table 10. Circulating Tumor DNA Diagnostics Market Trends
 Table 11. Circulating Tumor DNA Diagnostics Market Drivers
 Table 12. Circulating Tumor DNA Diagnostics Market Challenges
 Table 13. Circulating Tumor DNA Diagnostics Market Restraints
 Table 14. Global Circulating Tumor DNA Diagnostics Revenue by Players (2020-2025) & (US$ Million)
 Table 15. Global Circulating Tumor DNA Diagnostics Market Share by Players (2020-2025)
 Table 16. Global Top Circulating Tumor DNA Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Circulating Tumor DNA Diagnostics as of 2024)
 Table 17. Ranking of Global Top Circulating Tumor DNA Diagnostics Companies by Revenue (US$ Million) in 2024
 Table 18. Global 5 Largest Players Market Share by Circulating Tumor DNA Diagnostics Revenue (CR5 and HHI) & (2020-2025)
 Table 19. Global Key Players of Circulating Tumor DNA Diagnostics, Headquarters and Area Served
 Table 20. Global Key Players of Circulating Tumor DNA Diagnostics, Product and Application
 Table 21. Global Key Players of Circulating Tumor DNA Diagnostics, Date of Enter into This Industry
 Table 22. Mergers & Acquisitions, Expansion Plans
 Table 23. Global Circulating Tumor DNA Diagnostics Market Size by Type (2020-2025) & (US$ Million)
 Table 24. Global Circulating Tumor DNA Diagnostics Revenue Market Share by Type (2020-2025)
 Table 25. Global Circulating Tumor DNA Diagnostics Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 26. Global Circulating Tumor DNA Diagnostics Revenue Market Share by Type (2026-2031)
 Table 27. Global Circulating Tumor DNA Diagnostics Market Size by Application (2020-2025) & (US$ Million)
 Table 28. Global Circulating Tumor DNA Diagnostics Revenue Market Share by Application (2020-2025)
 Table 29. Global Circulating Tumor DNA Diagnostics Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 30. Global Circulating Tumor DNA Diagnostics Revenue Market Share by Application (2026-2031)
 Table 31. North America Circulating Tumor DNA Diagnostics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 32. North America Circulating Tumor DNA Diagnostics Market Size by Country (2020-2025) & (US$ Million)
 Table 33. North America Circulating Tumor DNA Diagnostics Market Size by Country (2026-2031) & (US$ Million)
 Table 34. Europe Circulating Tumor DNA Diagnostics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 35. Europe Circulating Tumor DNA Diagnostics Market Size by Country (2020-2025) & (US$ Million)
 Table 36. Europe Circulating Tumor DNA Diagnostics Market Size by Country (2026-2031) & (US$ Million)
 Table 37. Asia-Pacific Circulating Tumor DNA Diagnostics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 38. Asia-Pacific Circulating Tumor DNA Diagnostics Market Size by Region (2020-2025) & (US$ Million)
 Table 39. Asia-Pacific Circulating Tumor DNA Diagnostics Market Size by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Circulating Tumor DNA Diagnostics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 41. Latin America Circulating Tumor DNA Diagnostics Market Size by Country (2020-2025) & (US$ Million)
 Table 42. Latin America Circulating Tumor DNA Diagnostics Market Size by Country (2026-2031) & (US$ Million)
 Table 43. Middle East & Africa Circulating Tumor DNA Diagnostics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 44. Middle East & Africa Circulating Tumor DNA Diagnostics Market Size by Country (2020-2025) & (US$ Million)
 Table 45. Middle East & Africa Circulating Tumor DNA Diagnostics Market Size by Country (2026-2031) & (US$ Million)
 Table 46. Grail, Inc. Company Details
 Table 47. Grail, Inc. Business Overview
 Table 48. Grail, Inc. Circulating Tumor DNA Diagnostics Product
 Table 49. Grail, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2020-2025) & (US$ Million)
 Table 50. Grail, Inc. Recent Development
 Table 51. Guardant Health, Inc. Company Details
 Table 52. Guardant Health, Inc. Business Overview
 Table 53. Guardant Health, Inc. Circulating Tumor DNA Diagnostics Product
 Table 54. Guardant Health, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2020-2025) & (US$ Million)
 Table 55. Guardant Health, Inc. Recent Development
 Table 56. Biodesix, Inc. Company Details
 Table 57. Biodesix, Inc. Business Overview
 Table 58. Biodesix, Inc. Circulating Tumor DNA Diagnostics Product
 Table 59. Biodesix, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2020-2025) & (US$ Million)
 Table 60. Biodesix, Inc. Recent Development
 Table 61. Exosome Diagnostics Company Details
 Table 62. Exosome Diagnostics Business Overview
 Table 63. Exosome Diagnostics Circulating Tumor DNA Diagnostics Product
 Table 64. Exosome Diagnostics Revenue in Circulating Tumor DNA Diagnostics Business (2020-2025) & (US$ Million)
 Table 65. Exosome Diagnostics Recent Development
 Table 66. Freenome Inc. Company Details
 Table 67. Freenome Inc. Business Overview
 Table 68. Freenome Inc. Circulating Tumor DNA Diagnostics Product
 Table 69. Freenome Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2020-2025) & (US$ Million)
 Table 70. Freenome Inc. Recent Development
 Table 71. LungLife AI, Inc. Company Details
 Table 72. LungLife AI, Inc. Business Overview
 Table 73. LungLife AI, Inc. Circulating Tumor DNA Diagnostics Product
 Table 74. LungLife AI, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2020-2025) & (US$ Million)
 Table 75. LungLife AI, Inc. Recent Development
 Table 76. Inivata Ltd. Company Details
 Table 77. Inivata Ltd. Business Overview
 Table 78. Inivata Ltd. Circulating Tumor DNA Diagnostics Product
 Table 79. Inivata Ltd. Revenue in Circulating Tumor DNA Diagnostics Business (2020-2025) & (US$ Million)
 Table 80. Inivata Ltd. Recent Development
 Table 81. Personal Genome Diagnostics, Inc. Company Details
 Table 82. Personal Genome Diagnostics, Inc. Business Overview
 Table 83. Personal Genome Diagnostics, Inc. Circulating Tumor DNA Diagnostics Product
 Table 84. Personal Genome Diagnostics, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2020-2025) & (US$ Million)
 Table 85. Personal Genome Diagnostics, Inc. Recent Development
 Table 86. CellMax Life Company Details
 Table 87. CellMax Life Business Overview
 Table 88. CellMax Life Circulating Tumor DNA Diagnostics Product
 Table 89. CellMax Life Revenue in Circulating Tumor DNA Diagnostics Business (2020-2025) & (US$ Million)
 Table 90. CellMax Life Recent Development
 Table 91. Research Programs/Design for This Report
 Table 92. Key Data Information from Secondary Sources
 Table 93. Key Data Information from Primary Sources
 Table 94. Authors List of This Report


List of Figures
 Figure 1. Circulating Tumor DNA Diagnostics Picture
 Figure 2. Global Circulating Tumor DNA Diagnostics Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Circulating Tumor DNA Diagnostics Market Share by Type: 2024 VS 2031
 Figure 4. Test Kits Features
 Figure 5. Reagents Features
 Figure 6. Global Circulating Tumor DNA Diagnostics Market Size by Application (2020-2031) & (US$ Million)
 Figure 7. Global Circulating Tumor DNA Diagnostics Market Share by Application: 2024 VS 2031
 Figure 8. Hospitals Case Studies
 Figure 9. Diagnostics Laboratories Case Studies
 Figure 10. Research Laboratories Case Studies
 Figure 11. Academic Research Institutes Case Studies
 Figure 12. Circulating Tumor DNA Diagnostics Report Years Considered
 Figure 13. Global Circulating Tumor DNA Diagnostics Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 14. Global Circulating Tumor DNA Diagnostics Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 15. Global Circulating Tumor DNA Diagnostics Market Share by Region: 2024 VS 2031
 Figure 16. Global Circulating Tumor DNA Diagnostics Market Share by Players in 2024
 Figure 17. Global Top Circulating Tumor DNA Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Circulating Tumor DNA Diagnostics as of 2024)
 Figure 18. The Top 10 and 5 Players Market Share by Circulating Tumor DNA Diagnostics Revenue in 2024
 Figure 19. North America Circulating Tumor DNA Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 20. North America Circulating Tumor DNA Diagnostics Market Share by Country (2020-2031)
 Figure 21. United States Circulating Tumor DNA Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Canada Circulating Tumor DNA Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Europe Circulating Tumor DNA Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe Circulating Tumor DNA Diagnostics Market Share by Country (2020-2031)
 Figure 25. Germany Circulating Tumor DNA Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. France Circulating Tumor DNA Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. U.K. Circulating Tumor DNA Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Italy Circulating Tumor DNA Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Russia Circulating Tumor DNA Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Nordic Countries Circulating Tumor DNA Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Asia-Pacific Circulating Tumor DNA Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific Circulating Tumor DNA Diagnostics Market Share by Region (2020-2031)
 Figure 33. China Circulating Tumor DNA Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Japan Circulating Tumor DNA Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. South Korea Circulating Tumor DNA Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Southeast Asia Circulating Tumor DNA Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. India Circulating Tumor DNA Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Australia Circulating Tumor DNA Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Latin America Circulating Tumor DNA Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America Circulating Tumor DNA Diagnostics Market Share by Country (2020-2031)
 Figure 41. Mexico Circulating Tumor DNA Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Brazil Circulating Tumor DNA Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Middle East & Africa Circulating Tumor DNA Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa Circulating Tumor DNA Diagnostics Market Share by Country (2020-2031)
 Figure 45. Turkey Circulating Tumor DNA Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Saudi Arabia Circulating Tumor DNA Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. UAE Circulating Tumor DNA Diagnostics Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. Grail, Inc. Revenue Growth Rate in Circulating Tumor DNA Diagnostics Business (2020-2025)
 Figure 49. Guardant Health, Inc. Revenue Growth Rate in Circulating Tumor DNA Diagnostics Business (2020-2025)
 Figure 50. Biodesix, Inc. Revenue Growth Rate in Circulating Tumor DNA Diagnostics Business (2020-2025)
 Figure 51. Exosome Diagnostics Revenue Growth Rate in Circulating Tumor DNA Diagnostics Business (2020-2025)
 Figure 52. Freenome Inc. Revenue Growth Rate in Circulating Tumor DNA Diagnostics Business (2020-2025)
 Figure 53. LungLife AI, Inc. Revenue Growth Rate in Circulating Tumor DNA Diagnostics Business (2020-2025)
 Figure 54. Inivata Ltd. Revenue Growth Rate in Circulating Tumor DNA Diagnostics Business (2020-2025)
 Figure 55. Personal Genome Diagnostics, Inc. Revenue Growth Rate in Circulating Tumor DNA Diagnostics Business (2020-2025)
 Figure 56. CellMax Life Revenue Growth Rate in Circulating Tumor DNA Diagnostics Business (2020-2025)
 Figure 57. Bottom-up and Top-down Approaches for This Report
 Figure 58. Data Triangulation
 Figure 59. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS

Global Cell free Tumor DNA Detection Market Research Report 2025
Global ctDNA Detection Market Research Report 2025
Global Circulating Tumour DNA ctDNA Testing Market Research Report 2024
Global ctDNA Detection Kit Market Research Report 2024
Global Cell Free Circulating Tumor DNA ctDNA Market Research Report 2024
Global Liquid Biopsy Products Market Insights Forecast to 2030
Global Liquid Biopsy IVD Market Size Status and Forecast 2021 2027
Global Liquid Biopsy For Cancer Diagnostics Market Research Report 2024
Global Circulating Tumor DNA Test Kit Market Research Report 2024
ctDNA Methylation Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Liquid Tumor Biopsy Market Research Report 2024
Global Circulating Tumor Cell CTC Detection Market Research Report 2024
Global Circulating Tumor Cell Diagnostics Market Insights Forecast to 2030
Global CTC Detection Market Research Report 2025
Global Canine Tumor Screening Market Research Report 2024
Global Canine Liquid Biopsy Market Research Report 2024
Global Canine Cancer Detection Market Research Report 2024
Global Cell Free DNA cfDNA Testing Market Research Report 2024
Global Cell free DNA Mutation Diagnostics Market Research Report 2024
Global Canine Biopsy Services Market Research Report 2025
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions